CN-122012692-A - Use of lncRNA in preparation of products for diagnosing/preventing/treating non-alcoholic fatty liver disease

Abstract

The invention discloses application of lncRNA in preparing a product for diagnosing/preventing/treating non-alcoholic fatty liver disease, wherein the lncRNA is lncRNA Gm34654, the sequence of which is shown as SEQ ID No.1, the expression of lncRNA Gm34654 is down-regulated in a non-alcoholic fatty liver disease mouse model and a cell model, and the lncRNA has the function of reducing oxidative stress level and mitochondrial injury in the non-alcoholic fatty liver disease, and research on the lncRNA Gm34654 in the non-alcoholic fatty liver disease mouse model and the cell model shows that the lncRNA Gm34654 can improve cell injury and lipid deposition in the non-alcoholic fatty liver disease, so that the lncRNA Gm34654 plays a key role in the pathogenesis of the non-alcoholic fatty liver disease, and can be used in preparing related products for diagnosing/preventing/treating the non-alcoholic fatty liver disease.

Inventors

• LI YANXIANG
• YUAN HAOMING
• WANG JINHONG
• ZHANG MIAOMIAO

Assignees

• 山东第二医科大学

Dates

Publication Date

20260512

Application Date

20260206

Priority Date

20250207

Claims (10)

1. Use of lncrna for the preparation of a product for diagnosing/preventing non-alcoholic fatty liver disease.
2. 2. The use according to claim 1, characterized in that lncRNA is lncRNA Gm34654 with the sequence shown in seq ID No. 1.
3. 3. The use according to claim 1, characterized in that lncRNA Gm34654 is down-regulated in the non-alcoholic fatty liver disease mouse model and in the cell model.
4. 4. The use according to claim 1, characterized in that lncRNA Gm34654 is used as biomarker for screening non-alcoholic fatty liver disease drugs.
5. 5. The use according to claim 1, characterized in that lncRNA Gm34654 is used as biomarker for the preparation of a reagent for diagnosing/preventing nonalcoholic fatty liver disease, said reagent comprising at least a primer for amplifying lncRNA Gm 34654; the primer comprises a forward primer and a reverse primer; The sequence of the forward primer is shown as SEQ ID NO. 8; the reverse primer is shown as SEQ ID NO. 9.
6. 6. The use according to claim 1, characterized in that lncRNA Gm34654 reduces oxidative stress levels and mitochondrial damage in non-alcoholic fatty liver disease in mouse and cell models of non-alcoholic fatty liver disease.
7. 7. The lncRNA biomarker for diagnosing the non-alcoholic fatty liver disease is characterized by being lncRNA Gm34654, and the sequence of the lncRNA biomarker is shown as SEQ ID No. 1.
8. 8. A medicament for the treatment of non-alcoholic fatty liver disease, comprising at least lncRNA Gm34654.
9. 9. A kit for diagnosing non-alcoholic fatty liver disease, comprising at least a reagent for detecting the expression level of lncRNA Gm34654 gene.
10. 10. The kit of claim 9, wherein the reagents comprise primers for amplifying lncRNA Gm 34654; the primer comprises a forward primer and a reverse primer; The sequence of the forward primer is shown as SEQ ID NO. 8; the reverse primer is shown as SEQ ID NO. 9.

Description

Use of lncRNA in preparation of products for diagnosing/preventing/treating non-alcoholic fatty liver disease Technical Field The invention belongs to the technical field of genetic engineering, and particularly relates to application of lncRNA in preparation of a product for diagnosing/preventing/treating non-alcoholic fatty liver disease. Background With global trends of obesity and related metabolic syndromes, the prevalence of non-alcoholic fatty liver disease (NAFLD) is greatly increased, gradually becoming the primary cause of chronic liver disease in humans, and can directly lead to cirrhosis, hepatocellular carcinoma, etc., and affect the progress of other chronic metabolic diseases. However, NAFLD has become a global public health problem because of the unknown pathogenesis and no ideal therapeutic method. NAFLD is a clinical pathological syndrome of excessive deposition of intracellular fat in liver cells caused by alcohol removal and other well-defined liver-damaging factors. With the increasing incidence of global epidemic non-alcoholic fatty liver disease of obesity and hypermetabolic syndrome, it has now become an important public health issue of public concern. The prevalence rate of the global non-alcoholic fatty liver disease is up to 25.24%, about 28% -40% of adult population in the United states and European countries suffer from the non-alcoholic fatty liver disease, the prevalence rate of the non-alcoholic fatty liver disease in China is about 30%, and the non-alcoholic fatty liver disease is not up or down compared with the incidence rate in Western countries, and the non-alcoholic fatty liver disease is in a younger trend. The non-alcoholic fatty liver disease progresses slowly, and in general, the non-alcoholic fatty liver disease has no clinical symptoms, and liver dysfunction or fatty liver is often found in health examination or other diseases. However, as the disease progresses, a series of diseases such as simple fatty liver (liver fat accumulation), nonalcoholic steatohepatitis, liver fibrosis, cirrhosis and possible hepatocellular carcinoma appear. The pathogenesis of the nonalcoholic fatty liver disease is quite complex, and relates to environmental and genetic factors, hormone secretion, lipid peroxidation injury, immune response, oxidative stress, abnormal fat metabolism and the like, however, the mechanisms are not clear, an effective method for preventing and treating the nonalcoholic fatty liver disease is still lacked, medicines such as ursodeoxycholic acid, statins and the like are mainly used clinically for preventing and treating the nonalcoholic fatty liver disease, but the medicines increase liver burden after long-term administration, and part of medicines have toxic and side effects. Along with the global prevalence of obesity and exacerbation of metabolic diseases, the search for effective gene targets for the treatment of non-alcoholic fatty liver disease has great significance. Long non-coding RNAs (lncRNAs) belong to non-protein coding RNAs, meaning RNA transcripts exceeding 200 bp a long, lacking protein coding ability, playing a key role in many human diseases by regulating microRNAs. lncRNAs are important regulatory molecules, have moderate evolutionary conservation and specific transcription, and play a role in transcriptional regulation, epigenetic gene regulation and disease development. lncRNAs are widely involved in epigenetic regulation through direct or indirect interactions with chromatin, as important regulatory molecules, a very complex diverse biological process from normal development to human disease. At present, in the field of non-alcoholic fatty liver disease, related researches on lncRNA are few, chinese patent No. CN115990184A discloses an application of conservative lncRNA-CTHCC in preparation of medicines for delaying and/or treating non-alcoholic fatty liver disease, lncRNA-CTHCC knockout can obviously relieve and even reverse the non-alcoholic fatty liver disease, so that a theoretical basis and a medicine target are provided for clinical treatment of the non-alcoholic fatty liver disease, chinese patent No. CN112626197A discloses a preparation method of an lncRNA marker for non-alcoholic fatty liver disease, and 3 lncRNA sequencing data sets obtained through screening are subjected to differential lncRNA expression analysis, and expression is up-regulated in a mouse NASH model. Clearly, the evidence disclosed in the prior art shows that lncRNA and corresponding gene targets can be used to improve lipid metabolism associated with non-alcoholic fatty liver disease, but research on directly serving as a biomarker for non-alcoholic fatty liver disease and reducing oxidative stress and a series of physiological processes caused by abnormal lipid metabolism by improving lipid metabolism associated with non-alcoholic fatty liver disease has not been seen. Therefore, based on the important role of lncRNA in the treatment of non-alcoholic fat